PE20212267A1 - Nuevas capsides de aav y composiciones que las contienen - Google Patents

Nuevas capsides de aav y composiciones que las contienen

Info

Publication number
PE20212267A1
PE20212267A1 PE2021001795A PE2021001795A PE20212267A1 PE 20212267 A1 PE20212267 A1 PE 20212267A1 PE 2021001795 A PE2021001795 A PE 2021001795A PE 2021001795 A PE2021001795 A PE 2021001795A PE 20212267 A1 PE20212267 A1 PE 20212267A1
Authority
PE
Peru
Prior art keywords
novel aav
compositions containing
capsides
aav capsides
novel
Prior art date
Application number
PE2021001795A
Other languages
English (en)
Inventor
Kalyani Nambiar
James M Wilson
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of PE20212267A1 publication Critical patent/PE20212267A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

En la presente se proporcionan nuevas capsides de AAV y rAAV que las comprenden. En una forma de realizacion, los vectores que utilizan una nueva capside de AAV demuestran una transduccion mayor de un tejido diana seleccionado en comparacion con un AAV del arte previo
PE2021001795A 2019-04-29 2020-04-28 Nuevas capsides de aav y composiciones que las contienen PE20212267A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962840184P 2019-04-29 2019-04-29
US201962913314P 2019-10-10 2019-10-10
US201962924095P 2019-10-21 2019-10-21
PCT/US2020/030281 WO2020223236A1 (en) 2019-04-29 2020-04-28 Novel aav capsids and compositions containing same

Publications (1)

Publication Number Publication Date
PE20212267A1 true PE20212267A1 (es) 2021-11-30

Family

ID=73028724

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2021001788A PE20220014A1 (es) 2019-04-29 2020-04-28 Nuevas capsides de aav y composiciones que las contienen
PE2021001789A PE20212334A1 (es) 2019-04-29 2020-04-28 Nuevas capsides de aav y composiciones que las contienen
PE2021001795A PE20212267A1 (es) 2019-04-29 2020-04-28 Nuevas capsides de aav y composiciones que las contienen

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PE2021001788A PE20220014A1 (es) 2019-04-29 2020-04-28 Nuevas capsides de aav y composiciones que las contienen
PE2021001789A PE20212334A1 (es) 2019-04-29 2020-04-28 Nuevas capsides de aav y composiciones que las contienen

Country Status (15)

Country Link
US (3) US20220220453A1 (es)
EP (3) EP3962507A4 (es)
JP (3) JP2022530656A (es)
KR (3) KR20220004681A (es)
CN (3) CN113853209A (es)
AU (3) AU2020264975A1 (es)
BR (3) BR112021021502A2 (es)
CA (3) CA3134379A1 (es)
CL (3) CL2021002768A1 (es)
CO (3) CO2021015924A2 (es)
IL (3) IL287498A (es)
MX (3) MX2021013266A (es)
PE (3) PE20220014A1 (es)
SG (3) SG11202111373YA (es)
WO (3) WO2020223231A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022016528A (es) 2020-06-17 2023-06-02 Univ Pennsylvania Composiciones y métodos para el tratamiento de pacientes de terapia génica.
BR112023003310A2 (pt) 2020-08-24 2023-05-02 Univ Pennsylvania Vetores virais que codificam fusões de agonistas do receptor de glp-1 e usos dos mesmos no tratamento de doenças metabólicas
WO2022094078A1 (en) 2020-10-28 2022-05-05 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of rett syndrome
KR20230107619A (ko) 2020-11-11 2023-07-17 유럽피안 몰레큘러 바이올로지 래보러토리 유전자 치료를 위한 변형된 바이러스 입자
JP2023551903A (ja) 2020-12-01 2023-12-13 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組織特異的標的化モチーフを有する新規組成物及びそれを含有する組成物
EP4255500A1 (en) 2020-12-01 2023-10-11 The Trustees of The University of Pennsylvania Compositions and uses thereof for treatment of angelman syndrome
BR112023021971A2 (pt) 2021-04-23 2024-02-20 Univ Pennsylvania Composições com motivos de direcionamento específicos do cérebro e composições contendo os mesmos
AU2023211652A1 (en) 2022-01-25 2024-08-08 The Trustees Of The University Of Pennsylvania Aav capsids for improved heart transduction and detargeting of liver
WO2023168293A2 (en) * 2022-03-01 2023-09-07 The Trustees Of The University Of Pennsylvania Viral vector genome encoding an insulin fusion protein
WO2023168403A2 (en) * 2022-03-03 2023-09-07 The Trustees Of The University Of Pennsylvania Viral vectors encoding parathyroid hormone fusions and uses thereof in treating hypoparathyroidism
WO2023196893A1 (en) 2022-04-06 2023-10-12 The Trustees Of The University Of Pennsylvania Compositions and methods for treating her2 positive metastatic breast cancer and other cancers
WO2023196892A1 (en) 2022-04-06 2023-10-12 The Trustees Of The University Of Pennsylvania Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors
WO2024015966A2 (en) * 2022-07-15 2024-01-18 The Trustees Of The University Of Pennsylvania Recombinant aav having aav clade d and clade e capsids and compositions containing same
WO2024130070A2 (en) 2022-12-17 2024-06-20 The Trustees Of The University Of Pennsylvania Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof
WO2024130067A2 (en) 2022-12-17 2024-06-20 The Trustees Of The University Of Pennsylvania Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ618298A (en) * 2001-11-13 2015-04-24 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
JP5054975B2 (ja) * 2003-09-30 2012-10-24 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア アデノ随伴ウイルス（ａａｖ）の同源系統群、配列、それらを含有するベクターおよびそれらの用途
CN117363655A (zh) * 2005-04-07 2024-01-09 宾夕法尼亚大学托管会 增强腺相关病毒载体功能的方法
US20090317417A1 (en) * 2006-04-28 2009-12-24 The Trustees Of The University Of Pennsylvania Modified AAV Vectors Having Reduced Capsid Immunogenicity and Use Thereof
DK2826860T3 (en) * 2010-04-23 2018-12-03 Univ Massachusetts CNS targeting AAV vectors and methods for their use
US10837027B2 (en) * 2014-03-10 2020-11-17 Uniqure Ip B.V. Further improved AAV vectors produced in insect cells
WO2015191508A1 (en) * 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
EP3632923A1 (en) * 2015-01-16 2020-04-08 Voyager Therapeutics, Inc. Central nervous system targeting polynucleotides
PT3872085T (pt) * 2015-07-30 2023-04-13 Massachusetts Eye & Ear Infirmary Sequências de aav ancestrais e utilizações destas
EP3368054A4 (en) * 2015-10-28 2019-07-03 Voyager Therapeutics, Inc. REGULATORY EXPRESSION USING THE ADENO-ASSOCIATED VIRUS (AAV)
WO2017075338A2 (en) * 2015-10-29 2017-05-04 Voyager Therapeutics, Inc. Delivery of central nervous system targeting polynucleotides
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
AU2017267665C1 (en) * 2016-05-18 2023-10-05 Voyager Therapeutics, Inc. Modulatory polynucleotides
WO2018075798A1 (en) * 2016-10-19 2018-04-26 Adverum Biotechnologies, Inc. Modified aav capsids and uses thereof
US10550405B2 (en) * 2017-03-15 2020-02-04 The University Of North Carolina At Chapel Hill Rational polyploid adeno-associated virus vectors and methods of making and using the same
WO2018200419A1 (en) * 2017-04-23 2018-11-01 The Trustees Of The University Of Pennsylvania Viral vectors comprising engineered aav capsids and compositions containing the same
JOP20190269A1 (ar) * 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
TWI722310B (zh) * 2017-08-03 2021-03-21 美商航海家醫療公司 用於aav之遞送之組合物及方法

Also Published As

Publication number Publication date
CO2021015916A2 (es) 2021-11-30
EP3976077A4 (en) 2023-08-30
US20220204990A1 (en) 2022-06-30
KR20220004681A (ko) 2022-01-11
AU2020264976A1 (en) 2021-11-11
MX2021013267A (es) 2021-11-17
MX2021013268A (es) 2021-11-17
CL2021002811A1 (es) 2022-05-27
SG11202111102SA (en) 2021-11-29
CN113853207A (zh) 2021-12-28
CA3134468A1 (en) 2020-11-05
PE20220014A1 (es) 2022-01-11
BR112021020545A2 (pt) 2022-01-04
CA3134379A1 (en) 2020-11-05
MX2021013266A (es) 2021-11-17
AU2020266523A1 (en) 2021-11-04
EP3976077A1 (en) 2022-04-06
EP3976078A4 (en) 2023-08-30
AU2020264975A1 (en) 2021-11-11
WO2020223231A1 (en) 2020-11-05
IL287492A (en) 2021-12-01
BR112021020054A2 (pt) 2021-12-07
EP3962507A4 (en) 2023-10-11
WO2020223236A1 (en) 2020-11-05
CN113853208A (zh) 2021-12-28
EP3976078A1 (en) 2022-04-06
US20220220453A1 (en) 2022-07-14
SG11202111373YA (en) 2021-11-29
CL2021002768A1 (es) 2022-05-27
CL2021002824A1 (es) 2022-05-27
SG11202111375RA (en) 2021-11-29
IL287491A (en) 2021-12-01
JP2022530656A (ja) 2022-06-30
CO2021015924A2 (es) 2021-11-30
IL287498A (en) 2021-12-01
WO2020223232A1 (en) 2020-11-05
KR20220004695A (ko) 2022-01-11
KR20220004680A (ko) 2022-01-11
EP3962507A1 (en) 2022-03-09
BR112021021502A2 (pt) 2022-07-19
JP2022530633A (ja) 2022-06-30
PE20212334A1 (es) 2021-12-14
JP2022530544A (ja) 2022-06-29
CA3134507A1 (en) 2020-11-05
CN113853209A (zh) 2021-12-28
US20220249705A1 (en) 2022-08-11
CO2021015928A2 (es) 2021-11-30

Similar Documents

Publication Publication Date Title
PE20212267A1 (es) Nuevas capsides de aav y composiciones que las contienen
MX2023001863A (es) Nuevas cápsides de aav y composiciones que las contienen.
ES2984259T3 (es) Capside de aav modificada con peptidos
CL2019000167A1 (es) Novedosas proteínas de la cápside del virus adenoasociado.
CL2020001360A1 (es) Cápsides variantes de virus adenoasociados y su uso para inhibir la angiogénesis.
PE20201264A1 (es) Variantes de capsides de virus adenoasociados y metodos de uso de estas
UY38003A (es) Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas
AR115097A1 (es) Vectores virales adenoasociados dirigidos al hígado
UY37863A (es) Virus adenoasociado (aav) con dominio de fosfolipasa modificado
CL2023001793A1 (es) Anticuerpos anti-componente de complemento y métodos de uso
UY37376A (es) Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso
BR112023022318A2 (pt) Capsídeos de aav e seu uso
UY38733A (es) Construcciones de arni para inhibir la expresión de scap y métodos de uso de las mismas
EP4019642A4 (en) SEPARATE MODIFIED CAPSID PROTEIN VP1 FROM AAV5
CL2021002236A1 (es) Inserción de vectores de virus adeno-asociados de b-sarcoglicano y el tratamiento de distrofia muscular
BR112021025317A2 (pt) Tienilhidroxiisoxazolinas e derivados das mesmas
AR120259A1 (es) Variantes de aav3b con rendimiento mejorado de la producción y tropismo hepático
EA202192955A1 (ru) Новые капсиды aav и композиции, содержащие их
BR112021025305A2 (pt) Hidroxi-isoxazolinas e uso das mesmas como fungicidas
MX2024009186A (es) Cápsides de aav para mejorar la transducción cardiaca y desdireccionamiento del hígado.
BR112021025242A2 (pt) Hidróxi-isoxazolinas e derivados das mesmas
GB202304767D0 (en) Synthetic AAV Capsid
ES1293454Y (es) Recubrimiento absorbente del sudor
BR112021025700A2 (pt) Hidróxi-isoxazolinas e derivados das mesmas